Cyplasin Biomedical Ltd Announces Australian Patent for the recombinant production of its Antitumor Protein

03-Jun-2008

Cyplasin Biomedical Ltd announced that its Australian Patent application Nr 2002361168 has been granted on April 29th, 2008 and the notice of acceptance has been published in the Supplement to the Australian Official Journal of patents. The claims cover the production methods for Cyplasin in mammalian cells to arrive at the recombinant cytotoxic antitumor protein.

"From an economic as well as from a scientific point of view the approval of our patent application is important for our company since it protects our approach how to express and obtain a protein made in a tumor cell whereby it itself is cytotoxic to such cells", said Professor Christian Petzelt, Chief Scientific Officer of Cyplasin Biomedical Ltd.

Cyplasin-SC TM has demonstrated a selective ability to rapidly kill certain types of cancer cells while leaving normal non-cancerous cells untouched. Cyplasin-SC TM is a protein originally discovered and isolated by Professor Petzelt from a marine organism, the sea hare (Aplysia punctata). The protein can now be manufactured as a recombinant protein which allows the company to develop the protein as an anti-cancer therapeutic product. United States and European Patents have been issued to the Company covering the Cyplasin-SC TM protein.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances